Anti-VEGFR2 [IMC-1121B (Ramucirumab)]

Catalogue Number: AB03058-10.29-ABA

Manufacturer:	Vector Laboratories, Inc (ABA)
Type:	Recombinant Monoclonal
Alias:	Vascular endothelial growth factor receptor 2; kinase insert domain-containing receptor; KDR; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1; CD309; VEGFR-2; Cyramza; LY3009806; 947687-13-0
Shipping Condition:	Blue Ice
Unit(s):	100 ug
Host name:	Human
Clone:	IMC-1121B (Ramucirumab)
Isotype:
Immunogen:	The original antibody was generated by using phage display technology. A new library comprising the single VH paired with the variable light chain (VL) repertoire obtained from the original naive human library was constructed, followed by phage display-based selection.
Application:	FC, IHC, InVitroA, InVivoA, Crstapy

Overview
Datasheets

Additional Text

Gene Name

KDR

Gene ID

3791

Uniprot ID

P35968

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.

Application Notes

The antibody blocked the VEGFR2/VEGF interaction with an IC50 value of 1 nM and 0.8 nM for Fab and IgG1 fragments respectively. The binding affinity of the Fab and IgG fragments to VEGFR-2 was measured by surface plasmon resonance (Kd= 100 pM and 50 pM respectively). The IgG1 fragment was able to inhibit VEGF-stimulated VEGFR2 phosphorylation in endothelial cells. The epitope mapping of this antibody demonstrated the antibody interacted with the third immunoglobulin domain within the extracellular region of VEGFR2 (Lu et al, 2003; pmid:12917408). The antibody (IgG1) strongly inhibited VEGF-induced migration of human leukemia cells in vitro, and when administered in vivo, significantly prolonged survival of NOD-SCID mice inoculated with human leukemia cells. (Zhu et al, 2003; pmid:12646950). The Fab fragment was able to strongly block VEGFR2/VEGF interaction, resulting in potent inhibition of an array of biological activities of VEGF, including activation of the receptor and its signaling pathway, intracellular calcium mobilization, and migration and proliferation of endothelial cells. (Miao et al., 2006; pmid:16682007). The antibody has demonstrated some antitumor efficacy in humans, including a decrease in tumor vascularity (Spratlin et al, 2010; pmid:21222245). The structure of the Fab fragment alone and in complex with domain 3 of VEGFR2 was determined (Franklin et al, 2011; pmid:21827946).

Short Description

This reformatted human antibody was made using the variable domain sequences of the original Human Fab format for improved compatibility with existing reagents assays and techniques.

AB03058-10.29 Datasheet

Price

£525.00

-

Quantity
Unit Size

Find out about delivery